SavedAdd your journal

Journals / KONURALP TIP DERGİSİ / 2020 / Cilt: 12 - Sayı: 1

Are the conventional risk factors still valid for acute myeloid leukemia patients?

Abdulkerim YILDIZ
Senem MARAL
Murat ALBAYRAK
Çiğdem PALA
Pınar CÖMERT
Hacer Berna AFACAN ÖZTÜRK
Osman ŞAHİN
Pages
5–11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Demographic data and disease data were analyzed and response rates, overall survival (OS) and progression-free survival (PFS) rates were calculated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to investigate the survival data of patients with acute myeloid leukemia (AML) and to determine the risk factors that can be easily evaluated.
📊
Key Findings & Data:Method: A retrospective analysis was made of the AML patients admitted to our center between 2009-2018.
💡
Conclusion & Impact:Demographic data and disease data were analyzed and response rates, overall survival (OS) and progression-free survival (PFS) rates were calculated.
🔬Design:Research Article
📍Scope:2009-2018 Verileri
⚙️Variables:leukemia · survival · age

Abstract

Objective: The aim of this study was to investigate the survival data of patients with acute myeloid leukemia (AML) and to determine the risk factors that can be easily evaluated. Method: A retrospective analysis was made of the AML patients admitted to our center between 2009-2018. Demographic data and disease data were analyzed and response rates, overall survival (OS) and progression-free survival (PFS) rates were calculated. Factors affecting survival were determined using Cox-regression analysis. Results: A total of 119 patients were included in the study during the 9-year study period. Of these, 21 patients had secondary AML and 11 had acute promyelocytic leukemia (APL). The mean follow-up period was 12.43 ± 15.63 months. OS of all patients was 9.20 months and PFS was 7.23 months. Age and leukocyte count at the time of diagnosis were found to have a significant impact on both OS and PFS (p <0.05). Conclusion: In addition to genetic and molecular features, which are expensive and not easily available, the age and leukocyte count of AML patients remain important as prognostic factors.

🔖

Cite This Article

YILDIZ, A., MARAL, S., ALBAYRAK, M., PALA, Ç., CÖMERT, P., ÖZTÜRK, H. B. A., ŞAHİN, O. (2020). Are the conventional risk factors still valid for acute myeloid leukemia patients?. KONURALP TIP DERGİSİ, Cilt: 12 - Sayı: 1, 5–11. https://ajindex.com/articles/164666

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74
  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012;62(1):10-29
  3. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet (London, England). 2013;381(9865):484-95
  4. Padilha SL, Souza EJ, Matos MC, Domino NR. Acute myeloid leukemia: survival analysis of patients at a university hospital of Parana. Revista brasileira de hematologia e hemoterapia. 2015;37(1):21-7
  5. Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246-52
  6. Grimwade D. The changing paradigm of prognostic factors in acute myeloid leukaemia. Best practice & research Clinical haematology. 2012;25(4):419-25
  7. Liersch R, Muller-Tidow C, Berdel WE, Krug U. Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. British journal of haematology. 2014;165(1):17-38
  8. Duployez N, Willekens C, Marceau-Renaut A, Boudry-Labis E, Preudhomme C. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert review of hematology. 2015;8(1):43-56
  9. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA: a cancer journal for clinicians. 2002;52(6):363-71
  10. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47
  11. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-87
  12. Medinger M, Lengerke C, Passweg J. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. Cancer genomics & proteomics. 2016;13(5):317-29
  13. Mamez AC, Raffoux E, Chevret S, Lemiale V, Boissel N, Canet E, et al. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. Leukemia & lymphoma. 2016;57(10):2281-8
  14. Kuo KH, Callum JL, Panzarella T, Jacks LM, Brandwein J, Crump M, et al. A retrospective observational stu